Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Neuropathic pain in animal models of nervous system autoimmune diseases.
CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies.
No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability.
Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica.
[Clinically isolated syndrome.]
Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population.
The prevalence of incidental findings in multiple sclerosis patients.
Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Familial forms of multiple sclerosis and neuromyelitis optica at an MS center in Rio de Janeiro State, Brazil.
Lhermitte's Sign: The Current Status.
Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Enhanced Action Potential Passage Through the Node of Ranvier of Myelinated Axons via Proton Hopping.
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720).
Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation.
Autonomic dysreflexia in acute disseminated encephalomyelitis.
Social and economic burden of walking and mobility problems in multiple sclerosis.
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.
[White matter lesions, young age, female - differential diagnosis of multiple sclerosis and juvenile stroke].
Interview: Experiences targeting B cells for the treatment of multiple sclerosis.
Unmet Needs of Patients Feeling Severely Affected by Multiple Sclerosis in Germany: A Qualitative Study.
Emerging Subspecialties in Neurology: Palliative care.
Role of iNOS-NO-cGMP signaling in modulation of inflammatory and myelination processes.
Pages
« first
‹ previous
…
343
344
345
346
347
348
349
350
351
…
next ›
last »